-- Revenue grew 336.5% to $14.4 million from prior year (excluding ACT 
      Genomics) 
 
   -- Raises full year revenue outlook to $80 - $100 million (excluding ACT 
      Genomics) 
 
   -- IM8 contributed $5.7 million in Q1, with $2.8 million in March alone & 
      provides Q2 revenue projections 
 
   -- IM8 has more than 55,000 customers with 4.9 million servings delivered 
      and counting 
 
   -- Details of crypto strategy and Bitcoin adoption to be announced soon as 
      part of innovative treasury approach 

CHARLOTTE, N.C., June 12, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced unaudited financial results for the first quarter ended March 31, 2025, along with recent business updates.

First Quarter 2025 Financial Highlights

   -- Revenue from continuing operations of $17.3 million in the first quarter 
      2025, an increase of 169.9% as compared to the first quarter 2024. 
 
   -- Revenue from our consumer business1, normalized to exclude ACT Genomics, 
      of $14.4 million in the first quarter 2025, an increase of 336.5% as 
      compared to the first quarter 2024. 
 
   -- Gross profit from continuing operations of $7.3 million in the first 
      quarter 2025, an increase of 94.1% as compared to the first quarter 2024. 
 
   -- Adjusted EBITDA2 loss from continuing operations of $(6.5) million in the 
      first quarter 2025, an increase of 59.4% as compared to the first quarter 
      2024. 
 
   -- Adjusted EBITDA loss from our consumer business, normalized to exclude 
      ACT Genomics, of $(4.8) million in the first quarter 2025, an increase of 
      123.7% as compared to the first quarter 2024. 
 
   -- Cash and other short-term assets3 of $78.0 million and the Company 
      remained debt-free as of March 31, 2025. 

Management Commentary

Danny Yeung, Chief Executive Officer and Co-Founder, remarked: "The first quarter of 2025 marked an exceptionally strong start for Prenetics, with financial performance that significantly surpassed expectations and strategic advancements that position us for accelerated growth. We are thrilled to report robust momentum, with revenue increasing by an impressive 336.5% year-over-year to $14.4 million (excluding ACT Genomics).

Our strategic realignment towards the global consumer healthcare market is gaining tremendous traction. This strong start to the year is reflected in our revised full year outlook for the year in which we are raising our revenue expectations from $73 - $85 million to $80 - $100 million, reflecting the accelerating momentum across our business units. Additionally, we expect IM8's second quarter revenue to reach approximately $8.5 million, representing a 50% quarter-over-quarter increase.

We have made significant progress in our previously announced strategic review of ACT Genomics and anticipate concluding this process shortly. An announcement regarding the strategic decision on our ownership stake in ACT Genomics will be forthcoming.

With a robust financial foundation of $78 million in cash and short-term assets, we are uniquely positioned to propel continued innovation and growth, particularly within the transformative landscape of healthcare. We are actively pioneering innovative approaches to treasury management and capital allocation, strategically embracing a crypto strategy and Bitcoin adoption. In an era where healthcare demands unprecedented efficiency, security, and global accessibility, we believe forward-thinking companies must leverage digital assets and blockchain technologies to not only optimize shareholder value but also to revolutionize patient care and medical research. Our strong cash position and accelerating business fundamentals empower us with the agility to pursue strategic crypto initiatives that will enhance our competitive positioning in health tech, foster groundbreaking advancements, and drive unparalleled long-term value creation for a healthier future," concluded Mr. Yeung.

_______________

(1) Represents the prevention and consumer health segments of the Group, which include genetic testing services, health and wellness products, and the distribution of sports nutrition products.

(2) Adjusted EBITDA is a non-IFRS financial measure defined as loss for the period excluding (1) depreciation and amortization, (2) interest income, (3) other finance costs, (4) income tax credit, (5) amortization of deferred expenses, (6) employee equity-settled share-based payment expenses, (7) acquisition and transaction-related costs, (8) strategic realignment and discontinued products impact, (9) exchange gain or loss, net, (10) fair value loss on financial assets at fair value through profit or loss, (11) fair value loss/(gain) on warrant liabilities, (12) gain on partial disposal of an equity-accounted investee, (13) share of loss of equity-accounted investees, net of tax, and (14) loss/(profit) from discontinued operation, net of tax. These adjustments are made for items that may not be indicative of our business performance, including non-cash and/or non-recurring items.

(3) Represents current assets, including cash and cash equivalents of $48.0 million, financial assets at fair value through profit or loss of $10.6 million, and trade receivables of $4.5 million, amongst other accounting line items under current assets as of March 31, 2025.

Business Updates and Strategic Initiatives

IM8 Business Momentum:

IM8 has achieved remarkable success in just six months since launch, attracting over 55,000 customers and delivering more than 4.9 million servings of its flagship Daily Ultimate Essentials. Our industry-leading 91% subscription rate and an impressive average order value of US$109 highlight strong customer loyalty and robust growth. With shipping now extended to 31 countries worldwide, IM8 is rapidly expanding its global footprint and demonstrating significant market potential.

Strategic Crypto Advisory Initiatives:

Leveraging our strong cash position and robust business fundamentals, management is actively advancing our innovative treasury management approach by evaluating strategic crypto initiatives and Bitcoin adoption. We are in active discussions with leading crypto industry veterans and thought leaders to provide expert guidance on digital asset opportunities, which will significantly enhance our crypto strategy decision-making capabilities and strengthen our market positioning in the evolving digital asset space. This forward-thinking approach to corporate finance aims to optimize capital allocation and drive long-term shareholder value creation.

Outlook

The Company is increasing full-year 2025 revenue guidance to $80 to $100 million from the previously projected $73 to 85 million.

As IM8 continues to demonstrate exceptional growth, and with Q1 2025 revenue of $5.7 million, we expect IM8's second quarter revenue to reach approximately $8.5 million, representing growth of 50% quarter-over-quarter.

About Prenetics

Prenetics (NASDAQ:PRE), a leading health sciences company, is dedicated to advancing consumer and clinical health. Our consumer initiative is led by IM8, a health and wellness brand and Europa, one of the largest sports distribution companies in the USA. Each of Prenetics' units synergistically enhances our global impact on health, embodying our commitment to 'enhancing life through science'. To learn more about Prenetics, please visit prenetics.com.

About IM8

IM8 is the pinnacle of premium core nutrition, born from a collaboration between David Beckham as a co-founding partner, and an elite team of scientists spanning medical professionals, academia and space science. Combining cutting-edge science with nature's most potent ingredients, IM8 delivers a holistic, science-backed approach to health, empowering you to live your most vibrant life. IM8's flagship product, Daily Ultimate Essentials is an all-in-one powder supplement engineered to replace 16 different supplements in a delicious drink and is NSF Certified for Sport, non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors or sweeteners. IM8 is a subsidiary of Prenetics (NASDAQ: PRE), a leading global health sciences company dedicated to advancing consumer health. To learn more about IM8, please visit IM8health.com.

Investor Relations Contact:

investors@prenetics.com

PRE@mzgroup.us

Angela Cheung

Investor Relations / Corporate Finance

Prenetics Global Limited

angela.hm.cheung@prenetics.com

Forward-Looking Statements

This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company's goals, targets, projections, outlooks, beliefs, expectations, strategy, plans, objectives of management for future operations of the Company, and growth opportunities are forward-looking statements. In some cases, forward-looking statements can be identified by words or phrases such as "may," "will," "expect," "anticipate," "target," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. Forward-looking statements are based upon estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company, which involve inherent risks and uncertainties, therefore they should not be relied upon as being necessarily indicative of future results. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to: the Company's ability to further develop and grow its business, including new products and services; its ability to execute on its new business strategy in genomics, precision oncology, and specifically, early detection for cancer; the results of case control studies

and/or clinical trials; and its ability to identify and execute on M&A opportunities, especially in precision oncology. In addition to the foregoing factors, you should also carefully consider the other risks and uncertainties described in the "Risk Factors" section of the Company's most recent registration statement and the prospectus therein, and the other documents filed by the Company from time to time with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

Basis of Presentation

Non-IFRS Financial Measure has been provided in the financial statements tables included at the end of this press release. An explanation of this measure is also included below under the heading "Non-IFRS Financial Measure".

Unaudited Non-IFRS Financial Measures

To supplement Prenetics' consolidated financial statements prepared in accordance with International Financial Reporting Standards ("IFRS"), the Company is providing non-IFRS measure, adjusted EBITDA loss from continuing operations, total revenue from continuing operations, normalized to exclude ACT Genomics and total adjusted EBITDA from continuing operations, normalized to exclude ACT Genomics. This non-IFRS financial measure is not based on any standardized methodology prescribed by IFRS and are not necessarily comparable to similarly-titled measures presented by other companies. Management believes this non-IFRS financial measure is useful to investors in evaluating the Company's ongoing operating results and trends.

Management is excluding from some or all of its non-IFRS results (1) depreciation and amortization, (2) interest income, (3) other finance costs, (4) income tax credit, (5) amortization of deferred expenses, (6) employee equity-settled share-based payment expenses, (7) acquisition and transaction-related costs, (8) strategic realignment and discontinued products impact, (9) exchange gain or loss, net, (10) fair value loss on financial assets at fair value through profit or loss, (11) fair value loss/(gain) on warrant liabilities, (12) gain on partial disposal of an equity-accounted investee, and (13) share of loss of equity-accounted investees, net of tax -- items that may not be indicative of our business, results of operations, or outlook, including but not limited to non-cash and/ or non-recurring items. These non-IFRS financial measures are limited in value because they exclude certain items that may have a material impact on the reported financial results. Management accounts for this limitation by analyzing results on an IFRS basis as well as a non-IFRS basis and also by providing IFRS measures in the Company's public disclosures.

In addition, other companies, including companies in the same industry, may not use the same non-IFRS measures or may calculate these metrics in a different manner than management or may use other financial measures to evaluate their performance, all of which could reduce the usefulness of these non-IFRS measures as comparative measures. Because of these limitations, the Company's non-IFRS financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with IFRS. Investors are encouraged to review the non-IFRS reconciliations provided in the tables captioned "Reconciliation of loss for the period under IFRS and adjusted EBITDA loss from continuing operations (Non-IFRS)", "Total Revenue from continuing operations, Normalized to exclude ACT Genomics" and "Total adjusted EBITDA from continuing operations, Normalized to exclude ACT Genomics" set forth at the end of this document.

PRENETICS GLOBAL LIMITED

Unaudited consolidated statements of financial position

(All amounts in thousands of U.S. dollars ("$"))

 
                                                  March 31,     December 31, 
                                                      2025           2024 
   Assets 
   Property, plant and equipment                  $    7,073   $       7,811 
   Intangible assets                                  11,333          11,574 
   Goodwill                                           37,364          37,364 
   Interests in equity-accounted investees            67,884          68,223 
   Financial assets at fair value through 
    profit or loss - non-current                       1,103           1,103 
   Other non-current assets                            1,234           1,352 
                                                     -------      ---------- 
   Non-current assets                                125,991         127,427 
                                                     -------      ---------- 
   Deferred expenses - current                         1,492           3,549 
   Inventories                                         6,610           6,566 
   Trade receivables                                   4,462           5,242 
   Deposits, prepayments and other receivables         6,929           7,975 
   Amount due from a related company                       3               3 
   Financial assets at fair value through 
    profit or loss - current                          10,562          10,562 
   Cash and cash equivalents                          47,966          52,251 
                                                     -------      ---------- 
   Current assets                                     78,024          86,148 
                                                     -------      ---------- 
   Total assets                                   $  204,015   $     213,575 
                                                     =======      ========== 
   Liabilities 
   Deferred tax liabilities                       $    2,097   $       2,165 
   Warrant liabilities                                   237             175 
   Lease liabilities - non-current                     2,546           3,014 
   Other non-current liabilities                         323             324 
                                                     -------      ---------- 
   Non-current liabilities                             5,203           5,678 
                                                     -------      ---------- 
   Trade payables                                      4,137           3,668 
   Accrued expenses and other current 
    liabilities                                       10,231           9,312 
   Contract liabilities                                6,191           6,491 
   Lease liabilities - current                         2,604           2,758 
   Liabilities for puttable financial 
    instrument(5)                                     14,520          14,309 
   Tax payable                                            13              13 
                                                     -------      ---------- 
   Current liabilities                                37,696          36,551 
                                                     -------      ---------- 
   Total liabilities                                  42,899          42,229 
                                                     -------      ---------- 
   Equity 
   Share capital                                          20              19 
   Reserves                                          160,862         170,370 
                                                     -------      ---------- 
   Total equity attributable to equity 
    shareholders of the Company                      160,882         170,389 
   Non-controlling interests                             234             957 
                                                     -------      ---------- 
   Total equity                                      161,116         171,346 
                                                     -------      ---------- 
   Total equity and liabilities                   $  204,015   $     213,575 
                                                     =======      ========== 
 

PRENETICS GLOBAL LIMITED

Unaudited consolidated statements of profit or loss and other comprehensive income

(All amounts in thousands of U.S. dollars ("$") unless otherwise indicated)

 
                                    Three Months Ended 
                        ------------------------------------------ 
                         March 31,    December 31,       March 31, 
                            2025          2024          2024 
Continuing operations 
   Revenue              $    17,312   $    10,488   $     6,413 
   Direct costs(6)           (9,970)       (6,586)       (2,631) 
                         ----------    ----------    ---------- 
   Gross profit               7,342         3,902         3,782 
   Other income and 
    other net gain              312         1,293           748 
   Selling and 
    distribution 
    expenses(6)              (4,789)       (2,406)       (1,898) 
   Research and 
    development 
    expenses(6)              (2,416)       (2,579)       (2,731) 
   Administrative and 
    other operating 
    expenses(6)             (11,081)      (16,780)       (9,061) 
                         ----------    ----------    ---------- 
   Operating loss from 
    continuing 
    operations              (10,632)      (16,570)       (9,160) 
   Fair value loss on 
    financial assets 
    at fair value 
    through profit or 
    loss                         --        (8,728)           -- 
   Fair value 
    (loss)/gain on 
    warrant 
    liabilities                 (63)           31            81 
   Gain on partial 
   disposal of an 
   equity-accounted 
   investee                      --         1,244            -- 
   Share of loss of 
    equity-accounted 
    investees, net of 
    tax                        (309)         (869)         (216) 
   Other finance costs          (69)          (78)          (16) 
                         ----------    ----------    ---------- 
   Loss before 

(MORE TO FOLLOW) Dow Jones Newswires

June 12, 2025 08:30 ET (12:30 GMT)